scholarly journals Management of Andersson Lesion in Ankylosing Spondylitis Using the Posterior-Only Approach: A Case Series of 18 Patients

2018 ◽  
Vol 12 (6) ◽  
pp. 1017-1027 ◽  
Author(s):  
Ismail Shaik ◽  
Shekhar Yeshwant Bhojraj ◽  
Gautam Prasad ◽  
Premik Bhupendra Nagad ◽  
Priyank Mangaldas Patel ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Case Series ◽  
Andersson Lesion

scholarly journals TYPE III CAWLEY ANDERSSON LESION IN A CASE OF ANKYLOSING SPONDYLITIS

2014 ◽  
Vol 04 (02) ◽  
pp. 136-139
Author(s):  
Deepak Hegde ◽  
Ballal Arjun ◽  
Vinay Kumar C. ◽  
H. Ravindranath Rai
Keyword(s):  
Back Pain ◽  
Ankylosing Spondylitis ◽  
Morning Stiffness ◽  
Posterior Spinal Fusion ◽  
Chronic Inflammatory Disease ◽  
Inflammatory Back Pain ◽  
Type Iii ◽  
Lesion Type ◽  
Andersson Lesion ◽  
Spinal Ligament

Abstract:Ankylosing spondylitis (AS) is a chronic inflammatory disease that affects especially males in the second and third decades of life.1 The main clinical symptom is inflammatory back pain typically occurring at night and morning stiffness improving after exercise.1 Apart from syndesmophytes and ankylosis of the spine resulting in rigidity, in longstanding ankylosing spondylitis, also focal destructive 1 discovertebral lesions (Andersson lesions) can occur.1 The case we present here is of a 35 year old male patient who presented to us with the symptoms of pain of upper back and both shoulders for 6 years. Pain was followed with stiffness of the neck and shoulder. Radiography of the dorsolumbar spine revealed squaring of the vertebra, syndesmophytes, calcification of the anterior spinal ligament, end plate irregularity at D10-D11 level, ill defined sclerosis with fracture of the ankylosed spine, features consistent with Andersson lesion type III. He underwent posterior spinal fusion with good functional outcome.

scholarly journals Andersson lesion in ankylosing spondylitis

2013 ◽  
Vol 2013 (apr03 1) ◽  
pp. bcr2012008404-bcr2012008404 ◽  
Author(s):  
U. Dhakad ◽  
S. K. Das
Keyword(s):  
Ankylosing Spondylitis ◽  
Andersson Lesion

scholarly journals Spondylodiscitis in ankylosing spondylitis: Andersson lesion

2020 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
BN Shiva Prasad ◽  
HA Karthik Urala
Keyword(s):  
Ankylosing Spondylitis ◽  
Andersson Lesion

Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching

2021 ◽  
Vol 10 (2) ◽  
pp. 68-71
Author(s):  
Mansour Somaily ◽  
Hana Alahmari ◽  
Wejdan Abbag ◽  
Shahenda Yousif ◽  
Nawar Tayfour ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Activity Index ◽  
Case Series ◽  
Disease Activity Index ◽  
Local Data ◽  
Open Label ◽  
One Year

Background: A biosimilar version of infliximab ( CT-P13) was recently approved for use in Saudi Arabia. Clinical data support its use in the treatment of rheumatic disease, however, there is a lack of local data regarding the efficacy and tolerability of CT-P13 among patients with rheumatological disorders in Saudi Arabia. Objectives: To investigate the feasibility, tolerability and immunogenicity of switching from originator infliximab to biosimilar infliximab, CT-P13, in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and Behçet’s disease (BD). Methodology: The study included patients who were being treated with originator infliximab in the Department of Rheumatology in Khamis Mushayt General Hospital, Saudi Arabia, and were required to switch to biosimilar infliximab (CT-P13) between January 2018 and June 2019. Patient follow-up was carried out every three months for one year. The disease activity score 28 (DAS28) was used to assess RA severity. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score was used to measure disease activity in patients with AS, while BD disease activity was based on clinical assessment. Results: In total, 13 patients (six with RA, five with AS and two with BD) were switched to biosimilar infliximab. The majority (n = 11/13) remained on biosimilar infliximab throughout the follow-up period with no reported major adverse events. Overall, there was a significant improvement in RA disease activity following biosimilar treatment, with the mean DAS28 decreasing from 3.61±1.24 before biosimilar therapy to 2.63±1.54 one year after switching. Conclusion: In patients with AS, BD, or RA who switched from originator infliximab to the biosimilar, CT-P13, we did not observe any significant differences in tolerability or efficacy between biosimilar and originator. Furthermore, disease activity significantly declined in RA patients following biosimilar treatment

Sign in / Sign up

Export Citation Format

Share Document